Securities code: 600196 stock abbreviation: Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) No.: lin2022-022 bond Code: 143020 bond abbreviation: 17 Fuyao 01
Bond Code: 143422 bond abbreviation: 18 Fuyao 01
Bond Code: 155067 bond abbreviation: 18 Fuyao 02
Bond Code: 155068 bond abbreviation: 18 Fuyao 03
Bond Code: 175708 bond abbreviation: 21 Fuyao 01
Shanghai Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) (Group) Co., Ltd
The 65th meeting (interim meeting) of the 8th board of directors decided to announce that the board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
The 65th meeting (interim meeting) of the 8th board of directors of Shanghai Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) (Group) Co., Ltd. (hereinafter referred to as “the company”) was held on February 11, 2022. All directors attended the meeting by means of communication. The convening of the meeting was in accordance with the company law of the people’s Republic of China Other relevant laws and regulations and the provisions of the articles of association of Shanghai Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) (Group) Co., Ltd. The meeting considered and passed the following proposals:
Deliberated and passed the proposal on the equity incentive plan for directors and core managers of Shanghai Fosun Health Technology (Group) Co., Ltd.
It is agreed that the equity incentive plan for directors and core managers (hereinafter referred to as the “plan”) formulated by the holding subsidiary Shanghai Fosun Health Technology (Group) Co., Ltd. (hereinafter referred to as “Fosun health”) will grant incentive rights and interests to Fosun health, the directors and core managers of its holding and participating companies / units.
At the same time, it is agreed to authorize the management of the company or its authorized persons to deal with specific matters related to the plan, including but not limited to signing, revising and executing relevant agreements.
Since the incentive objects of the plan include Mr. Wu Yifang, Ms. Guan Xiaohui, Mr. Chen Qiyu, Mr. Yao Fang, Mr. Chen Yuqing, Mr. Li Shengli, Ms. Feng Rongli and Mr. Hu hang, the directors / senior managers of the company constitute the related parties and Its participation in the plan constitutes a related party transaction of the company.
Since the incentive objects of the plan include Mr. Wu Yifang, Ms. Guan Xiaohui, Mr. Chen Qiyu and Mr. Yao Fang, directors of the company, and several directors and supervisors of Fosun health, according to the provisions of the Securities Listing Rules of the stock exchange of Hong Kong Limited, these persons constitute connected persons of the company, and their participation in the plan constitutes connected transactions of the company.
When the board of Directors voted on this proposal, related / connected directors Mr. Wu Yifang, Ms. Guan Xiaohui, Mr. Chen Qiyu and Mr. Yao Fang avoided voting, and the remaining 7 directors (including 4 independent non-executive directors) of the board of directors participated in the voting.
Voting results: 7 in favor, 0 against and 0 abstention.
Independent non-executive directors have expressed their opinions on this proposal.
For details, please refer to the announcement on the equity incentive plan and related party transactions to be implemented by the holding subsidiary (Announcement No.: pro 2022-023) issued on the same day.
It is hereby announced.
Board of directors of Shanghai Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) (Group) Co., Ltd. February 11, 2002
